CASI Biopharmaceuticals

CASI Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, primarily in China and the United States. The company's portfolio includes a mix of internally developed drug candidates and licensed assets, with a strong emphasis on hematology-oncology. Their lead commercial product is EVOMELA (melphalan hydrochloride for injection), used in the treatment of multiple myeloma. CASI is also advancing a pipeline of novel therapies, including CAR-T cell treatments and monoclonal antibodies targeting various cancers. The company leverages its strategic presence in both the U.S. and China to bridge global drug development and commercialization.